Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financi...(4148 Deferred revenue ...),Health

Date:11/9/2009

4,148 Deferred revenue 2,458 1,539 Income taxes payable 1,970 1,568 Total current liabilities 35,300 41,774 Long-term debt, vendor financing and convertible debentures 22,465 23,709 Long-term deferred revenue 1,396 595 Long-term deferred tax liability 119 119 Total liabilities 59,280 66,197 Commitments and contingencies Stockholders' equity: Preferred stock, $.01 par value, 500,000 shares authorized, none issued -- -- Common stock, $.01 par value, 28,200,000 shares authorized, including 3,200,000 designated Class B: Common stock - 13,605,960 and 13,452,007 shares issued and outstanding at September 30, 2009 and March 31, 2009, respectively 136 135 Class B stock - 1,162,500 shares issued and outstanding at September 30, 2009 and March 31, 2009, respectively 12 12 Additional paid-in capital 97,684 95,808 Accumulated other comprehensive income 3,068 3,072 Retained earnings (accumulated deficit) 1,063 (2,587) Total stockholders' equity 101,963 96,440 Total liabilities and stockholders' equity $161,243 $162,637 CHINDEX INTERNATIONAL, INC. SEGMENT INFORMATION

The Comp
'/>"/>

SOURCE Chindex International, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
2. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
3. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women